Hansa Biopharma

European Organ Allocation Will Face Volatility Yet Allow Recovery

AnalystLowTarget

Not Invested

Community Contributor

Published

12 Aug 25

AnalystLowTarget's Fair Value

SEK 37.00

0.3% undervalued

04 Sep

SEK 36.88

-10.0%

-5.1%

-10.0%

-5.1%

You can edit this narrative until Aug 12 10:43 PM. Then, changes will post as Updates.

Author's Valuation

SEK 370.3% undervalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

SEK 37

0.3% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

44.61%

Biotech revenue growth rate

8.95%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

5.30%

Calculation

SEK 297.73m

Earnings '28

23.99x

PE Ratio '28

SEK 7.14b

Market Cap '28

SEK 7.14b

Market Cap '28

165.53m

No. shares '28

SEK 43.16

Share Price '28

SEK 43.16 Share Price '28

Discounted to 2025 @ 5.26% p.a.

SEK 37.00

Fair Value '25